Neurofibromatosis (NF) Registry Portal
Part of paid clinical trials in New York, New York.
- Sponsor
- The Children's Tumor Foundation
- Study ID
- NCT01885767
- Status
- Recruiting
Conditions
- Neurofibromatosis 1
- Neurofibromatosis 2
- Schwannomatosis
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to supply de-identified disease data to researchers. It has the potential to become a natural history resource.
Key Dates
- Start date
- Jun 30, 2012
- Status verified
- Aug 2023
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2050
Study Design
- Enrollment
- 20,000 participants (estimated)
Arms
- Arm: NF1Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
- Arm: NF2Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
- Arm: SchWPatients meeting clinical and/or genetic criteria for Schwannomatosis
Primary Outcome Measure
To create a natural history of NF1, NF2, and schwannomatosis [ Time Frame: final report in 2050 with descriptive statistics ]
Central Contacts
- Kate Kelts, B.S.N.646-738-8567
- Annette Bakker, Ph.D.212-344-7029
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Tumor Fundation | New York | New York | 10017 | Kate Kelts, B.S.N. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site
Related Studies
- A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaPHASE1/PHASE2 · Recruiting · Therapeutic Advances in Childhood Leukemia Consortium · Phoenix, Arizona
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)Recruiting · National Cancer Institute (NCI) · Washington D.C., District of Columbia
- Photodynamic Therapy for Benign Dermal Neurofibromas- Phase IIPHASE2 · Recruiting · Donald Basel · Milwaukee, Wisconsin
- RASopathy BiorepositoryRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio